To analyze the relationships between insight, medication adherence, addiction, coping and social support—components of Illness Management and Recovery (IMR)—as determinants of clinical, functional and personal recovery in patients with schizophrenia and other severe mental illnesses. Our rationale lay in the interrelations between these concepts suggested in a conceptual framework of IMR.
The cross-sectional design used baseline data of outpatient participants in a randomized clinical trial on IMR (N = 187). We used structural equation modeling (SEM) to describe pathways between degrees of insight, medication adherence, addiction, coping and social support, and degree of clinical, functional and personal recovery. We also explored whether clinical recovery mediated functional and personal recovery.
Our final model showed that coping was associated with clinical, functional and personal recovery. Direct associations between coping and functional and personal recovery were stronger than indirect associations via clinical recovery. Although SEM also showed a significant but weak direct pathway between social support and functional recovery, there were no significant pathways either between social support and clinical or personal recovery, or between insight, medication adherence, addiction and any type of recovery.
Coping may be a determinant of all three types of recovery, and social support a determinant of functional recovery. Clinical recovery appears not to be a prerequisite for functional or personal recovery. While our results also suggest the relevance of improving coping skills and of enhancing social support, they only partially support the conceptual framework of IMR.
Citation: Roosenschoon B-J, Kamperman AM, Deen ML, Weeghel Jv, Mulder CL (2019) Determinants of clinical, functional and personal recovery for people with schizophrenia and other severe mental illnesses: A cross-sectional analysis. PLoS ONE 14(9): e0222378. https://doi.org/10.1371/journal.pone.0222378
Editor: Sinan Guloksuz, Department of Psychiatry and Neuropsychology, Maastricht University Medical Center, NETHERLANDS
Received: March 5, 2019; Accepted: August 29, 2019; Published: September 18, 2019
Copyright: © 2019 Roosenschoon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: Data are stored at the institutional database of the Erasmus Medical Centre in Rotterdam, The Netherlands. Since the datasets on which the analyses are based contain sensitive patient information (e.g. illicit drug use) and information on the treating health care professional and time and place of treatment, the Local Ethics Committee of the Erasmus Medical Centre in Rotterdam posed ethical restrictions for public sharing. Datasets are available on request to the Local Ethics Committee of the Erasmus Medical Centre in Rotterdam. To request the data, please contact: Dr Astrid Kamperman: email@example.com or Dr Joke Tulen: firstname.lastname@example.org.
Funding: Most of the study was funded by Parnassia Psychiatric Institute (The Hague/ Rotterdam) https://www.parnassiagroep.nl/. The remainder was funded by an unconditional educational grant from Janssen-Cilag B.V. (1-4H1ZDZ67890) https://www.janssen.com/netherlands/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: AMK currently serves as an academic editor for PLOS ONE. This study was also funded by an unconditional educational grant from Janssen-Cilag B.V. (1-4H1ZDZ67890) https://www.janssen.com/netherlands/. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
In recent years the concept of recovery has become increasingly important, and is generating interest and optimism among various stakeholders, such as service users, providers and payers . Treatment success in mental healthcare for people with schizophrenia or other serious and persistent mental illnesses (SMI) is perceived more and more as progress in terms of the degree of recovery. However, recovery is a complex and multidimensional concept, and has been defined in various ways [2–4]. In a typology that is used throughout this paper, three types of recovery can be differentiated, which should not be considered as mutually exclusive, but as complementary aspects of recovery . In this typology recovery is regarded as an outcome and as a cross-sectional reflection of functional status . The first type is clinical or symptomatic recovery, which as defined in the present study, concerns the degree of psychiatric symptomatology [6–8]. This does not equate with symptomatic remission, i.e., the absence or a sustained reduction in symptoms over a certain period and scored below distinct thresholds [2, 7, 9–11].
The second type is functional recovery, also named objective recovery . While some authors equate this with functional remission [7, 9], others consider it to be part of clinical recovery [13–14]. Or they regard cognitive functioning as part of the definition [9, 15–16]. However, in the present study, functional recovery is defined as the degree of vocational and social functioning, such as acting according to age-appropriate role expectations, the performance of daily living tasks without supervision, engagement in social interactions , and the degree of independence with regard to housing [4, 9]. Functional recovery thus concerns functional outcomes rather than functional capacity [17–19].
The third type of recovery is personal recovery, a term that originated among people with lived experience of mental illness and also highlights the personal nature of the recovery process [20–21]. Sometimes named subjective recovery , it includes components such as spirituality, empowerment, actively accepting the illness, and also finding hope, re-establishing a positive identity, developing meaning in life, overcoming stigma, taking control of one’s own life, and having supporting relationships . In a shorter definition, it concerns the extents of perceived recovery, sense of purpose, and personal agency . To summarize the key elements of personal recovery, various authors use the acronym CHIME: connectedness; hope and optimism about the future; identity; meaning in life; and empowerment .
One program for promoting recovery is Illness Management and Recovery (IMR), a curriculum-based psychosocial program for people with SMI that is intended to improve various aspects of illness management and self-management; and also by helping participants to set and achieve personal goals. Its overall purpose is to foster clinical recovery and to support personal and functional recovery. The development of IMR was based on an empirical review of the research literature on teaching illness self-management strategies to people with SMI. In this review, five empirically supported strategies were distinguished: psychoeducation on SMI and its treatment, cognitive-behavioral techniques to medication adherence, developing a relapse prevention plan, enhancing social support by social skills training, and coping skills training for controlling persistent symptoms. Those five illness management strategies were integrated into the IMR program [12, 23]. The theoretical foundation of IMR rests on two models. The first, the trans-theoretical model, holds that people are more motivated to acquire new behavior if the types of intervention are adjusted to the stage of change they are in [24–25]. The second model is the stress-vulnerability model, which holds not only that mental health problems originate from the interaction between biological vulnerability and sources of stress in the environment, but also that people differ in their coping ability [12, 26–27].
The aim of our main study, a randomized clinical trial (RCT) on IMR, is to determine the effectiveness of the IMR program in people with SMI as described in our protocol . The design is to compare the effects of “IMR + Care as Usual (CAU)” with those of “CAU only” on illness management constituents and on the three types of recovery mentioned. Measurement was planned to take place before randomization and at 12 and 18 months after randomization. Generalized linear mixed models (GLMM) are used to investigate group differences between the experimental and control conditions over an 18 months period, including a 12 months treatment period and a 6 months follow-up period.
The working mechanisms of IMR are suggested in a conceptual framework in which better illness management leads to better clinical recovery, and better clinical recovery leads to more personal and functional recovery, see S1 Fig [12, 28]. For the present cross-sectional study we used the data of all 187 people who participated in the baseline measurement of our RCT on IMR. Aim of this analysis is to seek empirical support for any relationships between the concepts suggested in this conceptual framework, but without the input of the IMR-program. We used structural equation modeling (SEM) to develop a recovery-path model on the basis of the direct and indirect associations proposed in this framework. This considers the associations between various components of illness management and the degree of clinical, functional and personal recovery. These components of illness management include psychiatric insight, adherence to medication, substance use, coping and social support, all being important ingredients of the theoretical base of the IMR-training.
We also explored whether clinical recovery does indeed mediate the association between these constituents of illness management and functional and personal recovery. We hypothesized that while the five illness-management constituents had direct pathways to clinical recovery, they had indirect pathways, via clinical recovery, to functional and personal recovery. SEM is a convenient statistical method for exploring such direct and indirect relationships for inferential purposes in a cross-sectional analysis [29–31].
In this study baseline data were used of 187 people who agreed to participate in the Dutch RCT on IMR . There were four inclusion criteria for this RCT: (1) having severe and persistent mental illness (SMI), such as a psychotic disorder or a schizoaffective disorder with or without comorbid disorders such as substance abuse and personality disorders; (2) being aged between 18 and 65; (3) currently at or recently admitted to the outpatient mental health services at one of two participating mental healthcare institutions in the Rotterdam area in the Netherlands; and (4) being willing and able to give written informed consent. There were three exclusion criteria: (1) having already participated in IMR training; (2) being unable to give informed consent due to intellectual disabilities; and (3) insufficient knowledge of the Dutch language. Participants in the study were recruited through clinician referrals for IMR from one of the 14 participating community mental health teams.
In interviews with participating clients and their clinicians, research assistants collected information on social-demographic variables: age, gender, living situation, educational level, native country, and source of income, and on psychiatric history: length of treatment and number and length of hospital admissions. This information was later cross-validated in the electronic client files. During the interviews with clinicians, we collected the diagnoses that had previously been made by psychiatrists in the community mental health teams on the basis of clinical interviews: psychotic disorders, mood disorder and/or personality disorder. These were also cross-validated in the electronic client files. In these interviews with clients and clinicians, questionnaires were filled out on illness management, clinical, functional and personal recovery.
This study was conducted in accordance with the Declaration of Helsinki. The RCT was approved by the medical research ethics committee (MREC) at Erasmus MC Rotterdam (Netherlands), and accredited by the Dutch Central Committee on Research Involving Human Subjects (CCMO), and was registered under number NTR 5033 in the Dutch National Trial Register .
Illness management constituents.
Coping was assessed using the client-rated Coping Self-Efficacy Scale (CSES). As the 26 items of the CSES are rated on a scale of 0–10, total scores range from 0–260, with higher scores indicating higher self-efficacy for coping with challenges and threats. The CSES consists of three factors: using problem-focused coping (12 items); stopping unpleasant emotions and thoughts (9 items); and getting support from friends and family (5 items) . Social support was assessed using the client-rated Multidimensional Scale of Perceived Social Support (MSPSS), whose 12 items are rated on a scale of 1–7. Total scores therefore range from 12–84, with higher scores indicating higher perceived social support. The MSPSS has a three-subscale structure: family, friends, and significant others . Medication adherence was assessed using the treatment-adherence-subscale of the clinician-rated Service Engagement Scale (SES). As the four items of this subscale are rated on a scale of 0–3, possible total scores of the subscale range from 0–12, with higher scores indicating higher medication adherence. The total SES (14 items) includes four subscales: availability, collaboration, help-seeking, and treatment adherence . Psychiatric insight was measured using the client-rated Insight Scale (IS), which captures three dimensions of insight: perceived need for treatment, awareness of illness, and re-labelling symptoms as pathological . Total scores range from 0–12, with higher scores indicating better insight . Problems with a.) alcohol, or b.) drugs were assessed using one client-rated item (item 24) from the Addiction Severity Index (ASI). As the two sub-items of this item are each rated on a scale of 0–4, possible total scores range from 0–8, with higher scores indicating more substance-related problems. The ASI is a semi-structured interview designed to provide an overall assessment of the severity of problems in seven potential problem areas in substance-abusing patients: medical status, employment and support, drug use, alcohol use, legal status, family/social status, and psychiatric status [37–38].
Clinical recovery was operationalized as the score on the client-rated Brief Symptom Inventory (BSI), whose 53 items are rated on a scale of 0–4. Total mean scores were used, with higher scores indicating that a client’s symptoms are more severe. The BSI has nine dimensions: psychoticism, depression, somatization, phobic anxiety, obsessive compulsiveness, interpersonal sensitivity, anxiety, hostility, and paranoid ideation [39–41]. To reflect the degree of recovery, the scores were reversed: i.e. a higher total score represents a higher degree of clinical recovery.
Functional recovery was operationalized as the score on the Social Functioning Scale (SFS), a self-administered questionnaire that consists of 76 items with varying response formats. A higher score indicates more, or a higher frequency of, competent behavior. All items are assigned to seven subscales: social engagement/withdrawal; interpersonal behavior; pro-social activities; recreation; independence competence; independence performance; employment/occupation. Each subscale score is the sum of all item values of that subscale, and all subscale values are standardized and normalized to a scaled score (Mean = 100, SD = 15). The full SFS scale score is computed as the mean of the scaled scores of the seven subscales [42–43].
Personal recovery was operationalized as the score on the Mental Health Recovery Measure (MHRM), whose 30 items are rated on a scale of 0–4. Total mean scores were used, with higher scores indicating better personal recovery. The questionnaire consists of three subscales: self-empowerment, learning and new potentials, and spirituality [44–47].
First, Pearson correlations were computed for the five constituents of illness management we measured: insight, coping, social support, medication adherence, and problems with alcohol and drugs; and also for clinical, functional, and personal recovery. Three categories were used in our interpretation of correlations: weak [0.1, 0.3), moderate [0.3, 0.5) and strong [0.5) .
To test our recovery-path model, we used SEM. The major advantages of this analysis are the ability to identify direct and indirect pathways and corresponding errors and to examine the associations among multiple independent and dependent variables simultaneously .
Our IMR model was tested as follows. First, we fitted the full unconstrained model, i.e. a model including the full set of illness-management constituents (insight, coping, social support, alcohol and drug use, and medication adherence) as independent variables, and functional and personal recovery as dependent variables. Clinical recovery was included as a mediating variable; see S2 Fig. We estimated the size and significance of all direct and indirect paths. Then, in subsequent steps, we removed all paths that did not significantly contribute to the fit of the model. The fit of the final, simplified, model was then tested against the fit of the full model. A non-significant result indicates that the simplified model fits the data as well as the full model does.
To allow for deviation from multivariate normality of the data and missing data-points the fit of the path-model and of the path coefficients were estimated using the robust maximum likelihood estimation-method [49–50]. Chi2-tests with Satorra-Bentler correction were used to compare the fit of the nested models . The fit of the final model was evaluated using the following: Chi2 and p-value (p>.05) and Chi2/df ratio (where a ratio smaller than 1.5 indicates a good fit); the Comparative Fit Index (CFI)  and Tucker-Lewis Index (TLI)  (where values above .95 indicate a good fit); Root Mean Square Error of Approximation (RMSEA)  (where a value lower than.06 indicates a good fit); and Standardized Root Mean Square Residuals (SRMR) (where a value lower than.05 indicates a good fit).
As well as using statistical significance of path coefficients, three categories were used in our interpretation of the strength of the relationships: weak [0.2, 0.5), moderate [0.5, 0.8) or strong [0.8) . We used SPSS 23.0 for data-management and descriptive analyses . SEM-analyses were performed using MPlus version 7.4 software .
Modal participants were male, living alone, had a secondary educational level, had been born in the Netherlands, and had a psychotic disorder. The modal length of treatment was more than five years, they had been admitted at least three times, had been hospitalized for less than one year, and had an income from unemployment, invalidity or sickness benefit (see Table 1).
Table 2 presents the correlation coefficients of the constituents of illness management, and of degrees of clinical, functional, and personal recovery. Significant correlations are highlighted. The correlation of functional and personal recovery was strong. Clinical recovery had a moderate correlation with functional recovery, and a strong correlation with personal recovery. Functional recovery had a strong correlation with coping, a moderate correlation with social support, a weak negative correlation with medication adherence, and a weak correlation with alcohol and drug use. Personal recovery had a strong correlation with coping, a moderate correlation with social support, and a weak negative correlation with insight and medication adherence.
Structural equation modeling
In accordance with the paths we hypothesized, our exploration of the effects consisted of three pathways: 1. exploration of the direct pathways between illness-management constituents (coping, social support, psychiatric insight, addiction, treatment adherence) and clinical recovery; 2. exploration of the direct pathways between clinical recovery and functional and personal recovery; and 3. exploration of the indirect pathways that lie, via clinical recovery, between the constituents of illness management and functional and personal recovery.
First, we fitted a full, unconstrained model, i.e., a model containing all the paths between the full set of the specified illness-management components and the recovery variables. A simplified model was then constructed by subsequently removing all paths that did not significantly contribute to the fit of the model. The final model fitted the data well: Chi2 = 13.96; df = 11; Chi2/df = 1.27; p>0.05; CFI = 0.99; TLI = 0.98; RMSEA = 0.038 (90%CI = 0.000–0.090); SRMR = 0.028. This simplified model consisted of paths between coping, social support, clinical recovery, and functional and personal recovery. Table 3 shows all the direct and indirect path coefficients of the simplified model. Significant paths are shown in Fig 1.
Coping was highly significantly, directly and moderately associated with the degree of clinical and personal recovery. Coping was highly significantly, directly and weakly associated with the degree of functional recovery. Via clinical recovery, coping was found to have significant indirect pathways to functional and personal recovery. However the direct associations between coping and functional and personal recovery were much stronger than the indirect associations.
The SEM showed a minor significant direct pathway between social support and functional recovery; the small path coefficient suggested a weak association. There were no significant direct or indirect paths between social support and clinical or personal recovery. This was also the case between insight, medication adherence, addiction and any type of recovery; but this may have been because scores in these domains showed limited variance.
This study was cross-sectional in design, with baseline data for 187 clients from an RCT used to examine pathways between specific IMR components—insight, medication adherence, addiction, coping and social support—and degree of clinical, functional and personal recovery, utilizing SEM. We also sought to explore whether clinical recovery mediated functional and personal recovery. By using baseline data we did not seek to examine the impact of the IMR program but empirical support for the associations between the concepts proposed by the conceptual framework of IMR.
We found that coping was directly and strongly associated with personal and functional recovery; we also found that these associations were moderated only marginally by clinical recovery. Therefore, coping seems to be more important for the degree of functional and personal recovery than the level of clinical recovery is. We found a weak direct pathway between social support and functional recovery. Insight, medication adherence, alcohol and drug use were not associated with any type of recovery.
As Fig 1 shows, we found partial empirical support for the conceptual framework of IMR–see S1 Fig—(1) there was a strong, direct pathway between coping–a component of illness management—and the degree of clinical recovery; and (2) clinical recovery was associated, albeit marginally, with functional and personal recovery. However, in a divergence from the conceptual framework, there were strong, direct associations between coping and the degree of functional and personal recovery. Social support—also a component of illness management—was not associated with clinical recovery, but had a weak direct association with functional recovery. In another divergence from the conceptual framework, there were no relationships between the three other constituents of illness management we measured and the degree of clinical recovery . And, in a third divergence from the conceptual framework, clinical recovery appeared not to be a prerequisite for personal and functional recovery.
Our finding that clinical recovery was not a prerequisite for functional recovery is in line with the results of earlier studies that reported that functional recovery had occurred in certain patients despite continuing symptoms [58–60] and with another study that concluded that no sequential relationship could be suggested between symptomatic remission and functional remission . In line with our finding of a significant but weak pathway between clinical recovery and personal recovery, a recent meta-analysis showed that the association between clinical and personal recovery is small to medium, and that personal recovery was explained only partly by symptom severity. The same meta-analysis concluded that treatment and outcome monitoring of patients with schizophrenia spectrum disorders should pay attention separately to clinical and personal recovery .
Our results underscore the clinical relevance of interventions aiming to improve coping skills as a means of promoting progress in clinical, functional, and personal recovery, such as those in the IMR-modules “Coping with stress” and “Coping with problems and persistent symptoms”. And our findings also confirm the relevance of interventions that focus on improving social support in order to promote progress in functional recovery, the IMR-module “Building social support” being one such intervention.
The strengths of the study include a large sample size, a broad range of measures–including those addressing the components of recovery–and analyses that comprise a more comprehensive understanding of predictors of recovery.
As, in their view, recovery models and frameworks are founded mainly on qualitative studies and expert opinion, Slade et al. have indicated an evidence gap . Such a gap might be bridged by our study, which is based on the conceptual framework of IMR, uses quantitative data from standardized recovery measures, and aims explicitly to explore the determinants of clinical, functional and personal recovery.
And although most of our study population consisted of people with psychotic disorders, our inclusion of patients with other serious mental illnesses contributes to generalizability in this domain, and also to external validity.
Our study also has various limitations. First, although coping and personal recovery are different theoretical concepts, they may have some overlap. However, the content of most of the CSES items is different from that of the MHRM items, especially regarding the items of the two largest subscales of the CSES, (1) Use problem-focused coping and (2) Stop unpleasant emotions and thoughts. Secondly: due to our use of specific definitions and operationalization’s of the three differentiated types of recovery, the generalizability of our results is limited in concepts of recovery that have been defined otherwise.
The third limitation is our inability to find significant pathways between addiction, medication adherence or insight and the degree of clinical, personal and functional recovery. This may have lain in the fact that a majority of the participants in our study had few problems in these domains and therefore showed only limited variance on the scores.
Fourth, as our analysis was cross-sectional and not longitudinal, we were unable to determine temporal causality. And as our analysis was led by the directions of the associations suggested in the conceptual frame work of IMR, we did not explore reverse directions of the associations between the various concepts.
Potential future directions
We have chosen to use total scores of most measures. More specific results could be obtained, if analyses were repeated using subscales of the illness management constituents and of the MHRM, but also using other components of personal recovery, such as self-esteem or self-stigma. Secondly: the generalizability of this type of research on recovery could increase if there would be more uniformity in definitions and operationalization’s of the different types of recovery—see introduction. Thirdly: to gain more insight into the impact of addiction, medication adherence and insight on the different types of recovery a research population could be chosen having more variance on the scores on these domains. Fourth: to be able to determine temporal causality this study could be repeated with a longitudinal analysis.“
Our results suggest that coping is a determinant of all three types of recovery, and that social support is a determinant of functional recovery. Clinical recovery appears not to be a prerequisite for functional and personal recovery. Our results also suggest the relevance of improving coping skills for clinical, functional and personal recovery, and of fostering social support for functional recovery. The conceptual framework of IMR could be only partially supported.
We thank David Alexander and Patric Hudman for their careful reading of the manuscript.
- 1. Frese FJ 3rd, Knight EL, Saks E. Recovery from schizophrenia: with views of psychiatrists, psychologists, and others diagnosed with this disorder. Schizophr Bull. 2009;35(2):370–80. Epub 2009/03/24. pmid:19304812; PubMed Central PMCID: PMC2659312.
- 2. Jaaskelainen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6):1296–306. Epub 2012/11/23. pmid:23172003; PubMed Central PMCID: PMC3796077.
- 3. Bellack AS. Scientific and consumer models of recovery in schizophrenia: concordance, contrasts, and implications. Schizophr Bull. 2006;32(3):432–42. pmid:16461575; PubMed Central PMCID: PMC2632241.
- 4. Whitley R, Drake RE. Recovery: a dimensional approach. Psychiatr Serv. 2010;61(12):1248–50. Epub 2010/12/03. pmid:21123410.
- 5. Slade M, Leamy M, Bacon F, Janosik M, Le Boutillier C, Williams J, et al. International differences in understanding recovery: systematic review. Epidemiol Psychiatr Sci. 2012;21(4):353–64. Epub 2012/07/17. pmid:22794507.
- 6. Slade M, Amering M, Farkas M, Hamilton B, O'Hagan M, Panther G, et al. Uses and abuses of recovery: implementing recovery-oriented practices in mental health systems. World Psychiatry. 2014;13(1):12–20. Epub 2014/02/06. pmid:24497237; PubMed Central PMCID: PMC3918008.
- 7. Cavelti M, Kvrgic S, Beck EM, Kossowsky J, Vauth R. Assessing recovery from schizophrenia as an individual process. A review of self-report instruments. Eur Psychiatry. 2012;27(1):19–32. Epub 2011/12/02. pmid:22130177.
- 8. Van Eck RM, Burger TJ, Vellinga A, Schirmbeck F, de Haan L. The Relationship Between Clinical and Personal Recovery in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-analysis. Schizophr Bull. 2017. Epub 2017/10/17. pmid:29036720.
- 9. Harvey PD, Bellack AS. Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? Schizophr Bull. 2009;35(2):300–6. Epub 2009/01/08. pmid:19126634; PubMed Central PMCID: PMC2659311.
- 10. Andreasen NC, Carpenter WT Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441–9. Epub 2005/03/03. pmid:15741458.
- 11. San L, Ciudad A, Alvarez E, Bobes J, Gilaberte I. Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study. Eur Psychiatry. 2007;22(8):490–8. Epub 2007/10/02. pmid:17904337.
- 12. Mueser KT, Meyer PS, Penn DL, Clancy R, Clancy DM, Salyers MP. The Illness Management and Recovery program: rationale, development, and preliminary findings. Schizophr Bull. 2006;32 Suppl 1:S32–43. pmid:16899534; PubMed Central PMCID: PMC2685197.
- 13. Slade M. Personal recovery and Mentall Ilness, a guide for Mental Health Professionals. Cambridge, United Kingdom: Cambridge University Press; 2009.
- 14. Liberman R, Kopelowicz A. Recovery from schizophrenia: a challenge for the 21st century. Int Rev Psychiatry. 2002;(14):245–55.
- 15. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and f unctional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(3):473–9. Epub 2004/03/03. pmid:14992973.
- 16. Wunderink L, Sytema S, Nienhuis FJ, Wiersma D. Clinical recovery in first-episode psychosis. Schizophr Bull. 2009;35(2):362–9. Epub 2008/11/08. pmid:18990715; PubMed Central PMCID: PMC2659307.
- 17. Carrion RE, McLaughlin D, Goldberg TE, Auther AM, Olsen RH, Olvet DM, et al. Prediction of functional outcome in individuals at clinical high risk for psychosis. JAMA Psychiatry. 2013;70(11):1133–42. Epub 2013/09/06. pmid:24006090; PubMed Central PMCID: PMC4469070.
- 18. Patterson TL, Mausbach BT. Measurement of functional capacity: a new approach to understanding functional differences and real-world behavioral adaptation in those with mental illness. Annu Rev Clin Psychol. 2010;6:139–54. Epub 2010/03/26. pmid:20334554; PubMed Central PMCID: PMC3160788.
- 19. ICF (The International Classification of Functioning DaH. Towards a Common Language for Functioning, Disability and Health. Geneva: World Health Organization (WHO); 2002.
- 20. Deegan P. Recovery as a Self-Directed Process of Healing and Transformation. Occupational Therapy in Mental Health. 2002;17(3–4):5–21.
- 21. Mead S, Copeland ME. What recovery means to us: consumers’ perspectives. Community mental health journal. 2000;36:315–28. pmid:10933247
- 22. Leamy M, Bird V, Le Boutillier C, Williams J, Slade M. Conceptual framework for personal recovery in mental health: systematic review and narrative synthesis. Br J Psychiatry. 2011;199(6):445–52. Epub 2011/12/02. pmid:22130746.
- 23. Mueser K, Gingerich S (eds). Illness Management and Recovery Implementation Resource Kit. Rockville, Md: Substance Abuse and Mental Health Services Administration, Center for Mental Health Services; 2002.
- 24. Prochaska JO, DiClemente CC. The Transtheoretical Approach: Crossing the Traditional Boundaries of Therapy. Homewood, Ill: Dow-Jones/Irwin; 1984.
- 25. Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983;51(3):390–5. PubMed pmid:6863699.
- 26. Liberman RP, Mueser KT, Wallace CJ, Jacobs HE, Eckman T, Massel HK. Training skills in the psychiatrically disabled: learning coping and competence. Schizophr Bull. 1986;12:631–47. PubMed pmid:3810067.
- 27. Zubin J, Spring B. Vulnerability—a new view of schizophrenia. Journal of abnormal psychology. 1977;86(2):103–26. PubMed pmid:858828.
- 28. Roosenschoon BJ, Mulder C.L., Deen M.L., van Weeghel J. Effectiveness of Illness Management and Recovery (IMR) in the Netherlands: a randomised clinical trial; Study Protocol. BMC Psychiatry. 2016;16(73):11. pmid:26995361
- 29. Hoyle RH. Handbook of Structural Equation Modeling. New York: Guilford Press; 2012.
- 30. Alessandrini M, Lancon C, Fond G, Faget-Agius C, Richieri R, Faugere M, et al. A structural equation modelling approach to explore the determinants of quality of life in schizophrenia. Schizophr Res. 2016;171(1–3):27–34. Epub 2016/01/20. pmid:26781001.
- 31. Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, et al. Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. Schizophr Res. 2016;175(1–3):154–60. Epub 2016/05/23. pmid:27209527.
- 32. Chesney MA, Neilands TB, Chambers DB, Taylor JM, Folkman S. A validity and reliability study of the coping self-efficacy scale. British journal of health psychology. 2006;11:421–37. pmid:16870053; PubMed Central PMCID: PMC1602207.
- 33. Zimet GD, Powell SS, Farley GK, Werkman S, Berkoff KA. Psychometric characteristics of the Multidimensional Scale of Perceived Social Support. Journal of personality assessment. 1990;55:610–7. pmid:2280326.
- 34. Tait L, Birchwood M, Trower P. A new scale (SES) to measure engagement with community mental health services. Journal of mental health. 2002;11(2):191–8. pmid:21208145.
- 35. Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M. A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatr Scand. 1994;89:62–7. PubMed pmid:7908156.
- 36. Tait L, Birchwood M, Trower P. Predicting engagement with services for psychosis: insight, symptoms and recovery style. Br J Psychiatry. 2003;182:123–8. PubMed pmid:12562739.
- 37. McLellan AT, Luborsky L, Woody GE, O'Brien CP. An improved diagnostic evaluation i nstrument for substance abuse patients. The Addiction Severity Index. The Journal of n ervous and mental disease. 1980;168:26–33. PubMed pmid:7351540.
- 38. Hendriks VM, Kaplan CD, van Limbeek J, Geerlings P. The Addiction Severity Index: reliability and validity in a Dutch addict population. Journal of substance abuse treatment. 1989;6:133–41. pmid:2746712.
- 39. Derogatis LR. BSI Brief Symptom Inventory. Administration, Scoring, and Procedures Manual (4th Ed.). Minneapolis, MN: National Computer Systems; 1993.
- 40. Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med. 1983;13:595–605. pmid:6622612.
- 41. De Beurs E. Brief symptom inventory; handleiding. Leiden: The Netherlands: PITS BV; 2008.
- 42. Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S. The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry. 1990;157:853–9. PubMed pmid:2289094.
- 43. Iffland JR, Lockhofen D, Gruppe H, Gallhofer B, Sammer G, Hanewald B. Validation of the German Version of the Social Functioning Scale (SFS) for schizophrenia. PLoS One. 2015;10(4):e0121807. Epub 2015/04/04. pmid:25837711; PubMed Central PMCID: PMC4383577.
- 44. Young SL, Bullock W. A. The Mental Health Recovery Measure. Toledo, Ohio: University of Toledo, Department of Psychology; 2003.
- 45. Bullock WA. The Mental Health Recovery Measure. In: Campbell-Orde T CJ, Carpenter J, Leff HS, editor. Measuring the Promise of Recovery: A Compendium of Recovery Measures. Cambridge, MA: Evaluation Center and Human Services Research Institute; 2005.
- 46. Moradi M, Brouwers E.P.M., Van den Bogaard J., Van Nieuwenhuizen Ch. Authorized translation in Dutch of the Mental Health Recovery Measure (MHRM), University of Tilburg/ Tranzo. Tilburg, the Netherlands: University of Tilburg/ Tranzo; 2007.
- 47. van Nieuwenhuizen C, Wilrycx G, Moradi M, Brouwers E. Psychometric evaluation of the Dutch version of the mental health recovery measure (MHRM). The International journal of social psychiatry. 2014;60:162–8. pmid:23396286.
- 48. Cohen J. Statistical Power Analysis for Behavioral Sciences, Second Edition. Mahwah, NJ. 07430 USA: Lawrence Erlbaum Associates; 1988.
- 49. Savalei V. Small sample statistics for incomplete non-normal data: Extensions of complete data formulae and a Monte Carlo comparison. Structural Equation Modeling: A Multidisciplinary Journal. 2010;17:241–60.
- 50. Savalei V. Understanding Robust Corrections in Structural Equation Modeling. Structural Equation Modeling: A Multidisciplinary Journal. 2014;21(1):149–60.
- 51. Satorra A, Bentler, PM. A scaled difference chi-square test statistic for moment structure analysis, Economics Working Papers 412, Department of Economics and Business, Universitat Pompeu Fabra. A scaled difference chi-square test statistic for moment structure analysis. Business DoEa, editor. Universitat Pompeu Fabra.1999.
- 52. Bentler PM. Comparative fit indexes in structural models. Psychol Bull. 1990;107(2):238–46. Epub 1990/03/01. pmid:2320703.
- 53. Tucker L, Lewis C. A reliability coefficient for maximum likelihood factor analysis. Psychometrika. 1973;38(1):1–10.
- 54. Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives., 6, 1–55. Structural Equation Modeling. 1999;6(1):1–55.
- 55. Jöreskog K. A general method for analysis of covariance structures. Biometrika. 1970;57:239–51.
- 56. IBM Corporation. IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corporation; 2015.
- 57. Muthén LM, Muthén BO. Mplus User’s Guide. Seventh Edition ed. Los Angeles, CA: Muthén & Muthén; 1998–2012.
- 58. Strauss JS, Carpenter WT Jr. The prediction of outcome in schizophrenia. II. Relationships between predictor and outcome variables: a report from the WHO international pilot study of schizophrenia. Arch Gen Psychiatry. 1974;31(1):37–42. Epub 1974/07/01. PubMed pmid:4835985.
- 59. Harding CM, Brooks GW, Ashikaga T, Strauss JS, Breier A. The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. Am J Psychiatry. 1987;144(6):727–35. Epub 1987/06/01. pmid:3591992.
- 60. Harding CM, Brooks GW, Ashikaga T, Strauss JS, Breier A. The Vermont longitudinal study of persons with severe mental illness, I: Methodology, study sample, and overall status 32 years later. Am J Psychiatry. 1987;144(6):718–26. Epub 1987/06/01. pmid:3591991.
- 61. Kortrijk HE, Mulder CL, van der Gaag M, Wiersma D. Symptomatic and functional remission and its associations with quality of life in patients with psychotic disorder in Assertive Community Treatment teams. Compr Psychiatry. 2012;53(8):1174–80. Epub 2012/06/29. pmid:22738674.